<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<link rel="shortcut icon" href="images/favicon.ico" type="image/x-icon"/>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />


<meta name=description content="Ovarian Cancer Therapy Innovative Models Prolong Survival(OCTIPS)"/>
<meta name=DC.Description content="Ovarian Cancer Therapy Innovative Models Prolong Survival(OCTIPS)"/>
<meta name=robots content="index,follow"/><meta name=revisit content="15 days"/>
<title>Ovarian Cancer Therapy Innovative Models Prolong Survival(OCTIPS)</title>
<link href="images/comunV1R12.css" rel="stylesheet" type="text/css">
<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-42303493-1', '2020horizon.com');
  ga('send', 'pageview');

</script>
</head>


<body style="background:#FFFFFF">

<div class="box" >

<div class="header">
  <!-- inicio logo -->
  <div>
    <a class="cabecera left" href="http://www.2020-horizon.com/" title="http://www.2020-horizon.com/"></a>
  </div>
  <!-- fin logo -->
  <!-- start header right -->
  <div class="header_right right">
    <div class="sprite buscador right">
      <form name="buschome" id="buschome" action=fp7.php>
                        <input name="txtBus" id="txtBus" maxlength="70" style="color: #888888;" type="text" onblur="javascript:if(document.buschome.txtBus.value==''){document.buschome.txtBus.value='Topics, projects and participants';document.buschome.txtBus.style.color='#888888';}" onclick="javascript:if(document.buschome.txtBus.value=='Topics, projects and participants'){document.buschome.txtBus.value='';document.buschome.txtBus.style.color='#000000';}" value="Topics, projects and participants" />
                <input name="opBus" id="opBushome" type="hidden" value="0" />
        <button class="thoughtbot boton_gris right esquina7" style="width: 215px; height: 34px; margin-top: 6px;" onclick="javascript:if((document.buschome.txtBus.value.length<3)||(document.buschome.txtBus.value=='Topics, projects and participants')){alert('You must fill in the field for at least three characters to define conduct the search');return false; };" name="acBuscabt" id="acBuscarbt" type="submit" value="Search">
          Search        </button>
        <input name="lg" id="lg" type="hidden" value="en" /> 
        <input name="pgBus" id="pgBus" type="hidden" value="1" />
      </form>
    </div>
    <span class="idiomas right"> <!-- inicio barraidioma --> <a class = "sprite en_activo right" ></a><!-- fin barraidioma --></span> 
      </div>
  <!-- end header right -->
</div>
<!-- end header -->


 <div class="clear"></div>

<div class="form right"><div class="sh_top"></div>
      
        
        
        
        
        

        

        <div class="miFormulario right">
      
          <h3 class="titulo_verde sprite">Need funding for your R&D project?</h3>
          
          <form method="post" action="">
            <label>Describe your project</label>
                        <textarea name="Descripcion" rows="10" cols="50"></textarea>
           <div class="clear"></div>
            <label>Project estimated budget</label>
                        <input name="Importe" maxlength="255" type="text" value="">

            <label>Phone</label>
                        <input name="Telefono" maxlength="255" type="text" value="">

            <label>e-mail</label>
                        <input name="Email" maxlength="255" type="text"  value="">
            
            <label>First name, Last name</label>
                        <input name="Nombre" maxlength="255" type="text" value=""><br>
            
            <button class="thoughtbot boton_gris right esquina7" type="submit" name="Enviar" value="Enviar" style="height: 35px; margin-right: 50px; margin-top: 20px;    width: 145px;">Submit</button>
          </form>
        
          <div class="clear"></div>
    <div>
      <div class="info_econet  right"><a href="http://econet-consultants.com/"><b>Service provided by econet, s.l.</b></a><br/>
              </div>
      <a  href="http://econet-consultants.com/" class="logo_econet2 sprite left"></a>
    </div>
</div>
<div class="clear"></div>
<!--<div class="redes"><a href="#" class="linkedin right sprite"></a><a href="#" class="twitter right sprite"></a></div>
-->
</div>        
        
        
        
          



<div class="contenedor1 left">
                    
    <div class="tit_gris_grande left bold">
								<span class="text_flecha sprite">&nbsp;</span>Ovarian Cancer Therapy Innovative Models Prolong Survival(OCTIPS)
							</div>         
 	<div class="clear"></div>

	<div class="tit_topic_grande">Funded under 7th FWP (Seventh Framework Programme)<br><strong>Research area:</strong> <br/>HEALTH.2011.2.4.1-2 Translational research on cancers with poor prognosis</div>  


     
     <div class="clear"></div> 

    <div class="tit_gris_grande2 left  bold"><span class="text_flecha sprite">&nbsp;</span> COORDINATOR
    <div class="caja_participantes"><div class="participantes"><div class="paises right">ÖSTERREICH </div><a href="http://www.2020-horizon.com/MEDIZINISCHE-UNIVERSITAET-WIEN-p637g1.html">MEDIZINISCHE UNIVERSITAET WIEN</a></div>     </div>
    
        
    <div class="clear"></div>
    
      
     
    <div class="clear"></div>
    
       	 
   	<div class="contenedor2" style="font-weight: normal;">
<p>About 75% of advanced epithelial ovarian cancer (EOC) patients respond to first-line surgery and chemotherapy but most relapse and ultimately acquire platinum resistance which soon leads to death. Relapsed high grade serous ovarian cancer (HGSOC) is the single main cause of EOC-related morbidity and mortality (despite the fact that HGSOC is highly chemosensitive). We hypothesize that the primary tumour includes a small population of resistant cells that are ultimately responsible for relapse and that by targeting this population front-line we may prolong disease-free survival or even achieve cure. OCTIPS will use unique retrospective and novel prospective paired tumour samples collected at the time of diagnosis and relapse to identify and validate molecules and pathways responsible for relapse. This identification will employ cutting edge high throughput multiplatform analyses such as next generation sequencing, mRNA and miRNA expression arrays and SNP array. Known and newly defined molecules or pathways will be evaluated in innovative integrated cancer model systems, utilising cell lines and avian egg and murine xenografts. New therapies to target these molecules and pathways will be developed and validated in these model systems. In order to translate these findings into patient benefit, agents that target the relapsing cell population will be tested for tolerability, efficacy, ability to combine with first line chemotherapy and then in randomised first line trials by the OCTIPS consortium.<br/>By translating the clinical observation of treatment failures into innovative cancer models that mimic relapsed ovarian cancer, we will validate improved front-line therapeutic strategies to help prolong patient survival. The impact of this application is that it defines a highly rigorous approach to integrate the bedside to bench to bedside paradigm, leading to novel prognosis-changing strategies for the treatment of ovarian cancer patients.</p>
</div>
	<div class="resumen_datos" style="min-width: 670px;"><div class="datos right"><span class="left"><br/> 2012-01-01 <br/> 3964946 euro <br/> Small or medium-scale focused research project <br/> 2015-12-31 <br/> Execution <br/> 2999302 euro </span></div><br>Start Date:<br>Project Cost:<br>Contract Type:<br>End Date:<br>Project Status:<br>Project Funding:<br></div> </div>
	<div class="clear"></div>
	<div class="tit_gris_grande2 left  bold"><span class="text_flecha sprite">&nbsp;</span> PARTICIPANTS 
   		<div class="caja_participantes"><div class="participantes"><div class="paises right">UNITED KINGDOM </div><a href="http://www.2020-horizon.com/IMPERIAL-COLLEGE-OF-SCIENCE-TECHNOLOGY-AND-MEDICINE-p714g1.html">IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE</a></div><div class="participantes"><div class="paises right">DEUTSCHLAND </div><a href="http://www.2020-horizon.com/ALCEDIS-GMBH-p8633g1.html">ALCEDIS GMBH</a></div><div class="participantes"><div class="paises right">BELGIQUE-BELGIË </div><a href="http://www.2020-horizon.com/KATHOLIEKE-UNIVERSITEIT-LEUVEN-p1015g1.html">KATHOLIEKE UNIVERSITEIT LEUVEN</a></div><div class="participantes"><div class="paises right">UNITED KINGDOM </div><a href="http://www.2020-horizon.com/CYCLACEL-LIMITED-p8634g1.html">CYCLACEL LIMITED</a></div><div class="participantes"><div class="paises right">FRANCE </div><a href="http://www.2020-horizon.com/INSTITUT-NATIONAL-DE-LA-SANTE-ET-DE-LA-RECHERCHE-MEDICALE-(INSERM)-p44g1.html">INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)</a></div><div class="participantes"><div class="paises right">NEDERLAND </div><a href="http://www.2020-horizon.com/ERASMUS-UNIVERSITAIR-MEDISCH-CENTRUM-ROTTERDAM-p157g1.html">ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM</a></div><div class="participantes"><div class="paises right">DEUTSCHLAND </div><a href="http://www.2020-horizon.com/CHARITE-UNIVERSITAETSMEDIZIN-BERLIN-p464g1.html">CHARITE - UNIVERSITAETSMEDIZIN BERLIN</a></div><div class="participantes"><div class="paises right">UNITED KINGDOM </div><a href="http://www.2020-horizon.com/THE-UNIVERSITY-OF-EDINBURGH-p29g1.html">THE UNIVERSITY OF EDINBURGH</a></div><div class="participantes"><div class="paises right">ÖSTERREICH </div><a href="http://www.2020-horizon.com/EMERGENTEC-BIODEVELOPMENT-GMBH-p2805g1.html">EMERGENTEC BIODEVELOPMENT GMBH</a></div><div class="participantes"><div class="paises right">ISRAEL </div><a href="http://www.2020-horizon.com/INNOVO-MIMETICS-LIMITED-p8635g1.html">INNOVO MIMETICS LIMITED</a></div></div>     </div>
      </div>
</div><!--contenedor1-->
   <div class="clear"></div>
</div>
<div class="footer" style="text-align:center;">
Welcome to the beta 2020horizon.com website.<br>
© Copyright econet. All rights reserved. 
<br>
<div class="text_flecha2_1" style="tetx-size:10px;">

<script language="javascript" src="js/js_0_1.js"></script>
<script type='text/javascript'>
	avisolegal('http://www.2020-horizon.com/aviso_legal.php?lg=en','Legal notice and Privacy Policy');
</script>
</div>
<br>
<br>
<font style="font-size: 10px; color: #777777;">
“Website funded by the Plan Avanza 2 as part of Project “OFP - OpenFunding Platform, Where innovation meets Funding Open web-based innovation Platform” file number IST-090500-2011-23”
<br>
<br>
<div class="clear"></div>
<div style="text-align:center;width:100%;">


<table border=0 style="margin: 0 auto;text-align: left">
<tr>
<td style="vertical-align:top;">
<img alt="Ministerio de Industria, Energia y Turismo"  title="Ministerio de Industria, Energia y Turismo"  height="60px;"  src="images/Ministerio_de_Industria_Energia_Turismo.png">
</td>
<td >
&nbsp;&nbsp;
</td>
<td style="vertical-align:middle;">
<img alt="plan azanza2" title="plan azanza2" height="30px;" src="images/plan_avanza2.png">
</td>
<td>
&nbsp;&nbsp;
</td>
<td style="vertical-align:top;">
<img alt="FEDER" title="FEDER" height="75px;" src="images/FEDER.png">
</td>
</tr>
</table>
</div>
</font>
</div></body>
</html>
